Author: Shehata, Mahmoud M.; Kandeil, Ahmed; Mostafa, Ahmed; Mahmoud, Sara H.; Gomaa, Mokhtar R.; El-Shesheny, Rabeh; Webby, Richard; Kayali, Ghazi; A. Ali, Mohamed
Title: A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice Document date: 2019_12_2
ID: 15q6qr4z_18
Snippet: The novel chimeric bivalent 5 + 3 vaccinated mice showed that a significant increase of nAbs against MERS-CoV occurs at week 8. Mice vaccinated with the chimeric bivalent virus were protected from mortality and body weight loss at 2 weeks of challenge with wild type H1N1pdm09 virus. At week 4, an apparent decline in antibody levels of specific immune response was observed. This is likely related to a traditional phenomenon, namely self-limitation.....
Document: The novel chimeric bivalent 5 + 3 vaccinated mice showed that a significant increase of nAbs against MERS-CoV occurs at week 8. Mice vaccinated with the chimeric bivalent virus were protected from mortality and body weight loss at 2 weeks of challenge with wild type H1N1pdm09 virus. At week 4, an apparent decline in antibody levels of specific immune response was observed. This is likely related to a traditional phenomenon, namely self-limitation or resolution, in which the neutralizing antibodies titer is decreased following the booster immunization as a response to the administrated antigens [24, 25] . Several studies showed that the protective efficacy of MERS-CoV vaccines positively correlates with the evoked neutralizing antibody titers in the serum of vaccinated animals [26, 27] . These results are in accordance with the results of other viral platforms chimeric viruses carrying spike protein which provided nAbs against MERS-CoV [9, 28] .
Search related documents:
Co phrase search for related documents- antibody level and body weight: 1
- antibody level and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- antibody level and MERS CoV vaccine: 1
- antibody level and neutralize antibody: 1
- antibody level and protective efficacy: 1, 2, 3
- antibody level and significant increase: 1, 2, 3, 4, 5, 6
- antibody level and specific immune response: 1, 2, 3
- antibody level and spike protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48
- antibody level and vaccinated mouse: 1
- antibody level and wild type: 1, 2, 3, 4, 5, 6, 7, 8, 9
- antibody titer and body weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- antibody titer and body weight loss: 1
- antibody titer and booster immunization: 1, 2
- antibody titer and chimeric virus: 1, 2
- antibody titer and immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- antibody titer and MERS CoV vaccine: 1, 2
- antibody titer and protective efficacy: 1, 2
- antibody titer and significant increase: 1, 2, 3, 4, 5, 6, 7
- antibody titer and specific immune response: 1, 2, 3, 4, 5, 6, 7, 8
Co phrase search for related documents, hyperlinks ordered by date